Literature DB >> 21502993

Rethinking the metastatic cascade as a therapeutic target.

Lida A Mina1, George W Sledge.   

Abstract

Metastasis is the leading cause of cancer death. The metastatic cascade is a complex yet inefficient process that we have only begun to understand in recent years. Several of the early steps of this cascade are not readily targetable in the clinic. Past therapeutic developmental strategies have not distinguished between micrometastases and overt metastases. This lack of understanding is apparent in therapies that have been developed for patients with metastatic disease that are not efficacious in patients with micrometastatic disease; that is, in the adjuvant setting. Moreover, drugs that target distant metastases often do not work in the adjuvant setting. This Review will discuss our current understanding of the metastatic cascade as it relates to therapy, emerging therapeutic targets in the metastatic process, and how novel antimetastatic therapies might be developed for clinical use.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21502993     DOI: 10.1038/nrclinonc.2011.59

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  87 in total

1.  Fibroblast growth factor-1 stimulates branching and survival of myocardial arteries: a goal for therapeutic angiogenesis?

Authors:  P Carmeliet
Journal:  Circ Res       Date:  2000-08-04       Impact factor: 17.367

Review 2.  Metastasis to bone: causes, consequences and therapeutic opportunities.

Authors:  Gregory R Mundy
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

Review 3.  Does tumour dormancy offer a therapeutic target?

Authors:  Paul E Goss; Ann F Chambers
Journal:  Nat Rev Cancer       Date:  2010-11-04       Impact factor: 60.716

4.  Dormancy of mammary carcinoma after mastectomy.

Authors:  T G Karrison; D J Ferguson; P Meier
Journal:  J Natl Cancer Inst       Date:  1999-01-06       Impact factor: 13.506

5.  Altered expression of NM23, a gene associated with low tumor metastatic potential, during adenovirus 2 Ela inhibition of experimental metastasis.

Authors:  P S Steeg; G Bevilacqua; R Pozzatti; L A Liotta; M E Sobel
Journal:  Cancer Res       Date:  1988-11-15       Impact factor: 12.701

Review 6.  MicroRNAs and metastasis: little RNAs go a long way.

Authors:  Derek M Dykxhoorn
Journal:  Cancer Res       Date:  2010-07-27       Impact factor: 12.701

7.  A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors.

Authors:  Matthew M Seavey; Zhen-Kun Pan; Paulo C Maciag; Anu Wallecha; Sandra Rivera; Yvonne Paterson; Vafa Shahabi
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

8.  Adaptive immunity maintains occult cancer in an equilibrium state.

Authors:  Catherine M Koebel; William Vermi; Jeremy B Swann; Nadeen Zerafa; Scott J Rodig; Lloyd J Old; Mark J Smyth; Robert D Schreiber
Journal:  Nature       Date:  2007-11-18       Impact factor: 49.962

9.  Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.

Authors:  S A Rosenberg; J C Yang; S L Topalian; D J Schwartzentruber; J S Weber; D R Parkinson; C A Seipp; J H Einhorn; D E White
Journal:  JAMA       Date:  1994 Mar 23-30       Impact factor: 56.272

10.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Authors:  John M L Ebos; Christina R Lee; William Cruz-Munoz; Georg A Bjarnason; James G Christensen; Robert S Kerbel
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

View more
  50 in total

1.  Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes.

Authors:  Sébastien Tabariès; Fanny Dupuy; Zhifeng Dong; Anie Monast; Matthew G Annis; Jonathan Spicer; Lorenzo E Ferri; Atilla Omeroglu; Mark Basik; Eitan Amir; Mark Clemons; Peter M Siegel
Journal:  Mol Cell Biol       Date:  2012-05-29       Impact factor: 4.272

2.  Targeting the ERK pathway reduces liver metastasis of Smad4-inactivated colorectal cancer.

Authors:  Xi Ai; Yanhui Wu; Wei Zhang; Zhanguo Zhang; Guannan Jin; Jianping Zhao; Jingjing Yu; Youzhi Lin; Wanguang Zhang; Huifang Liang; Pran K Datta; Mingzhi Zhang; Bixiang Zhang; Xiaoping Chen
Journal:  Cancer Biol Ther       Date:  2013-09-12       Impact factor: 4.742

Review 3.  Salting the Soil: Targeting the Microenvironment of Brain Metastases.

Authors:  Ethan S Srinivasan; Aaron C Tan; Carey K Anders; Ann Marie Pendergast; Dorothy A Sipkins; David M Ashley; Peter E Fecci; Mustafa Khasraw
Journal:  Mol Cancer Ther       Date:  2021-01-05       Impact factor: 6.261

4.  Circulating Tumor Cells: When a Solid Tumor Meets a Fluid Microenvironment.

Authors:  Katarzyna A Rejniak
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

5.  Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer.

Authors:  Yekaterina Y Zaytseva; Piotr G Rychahou; Pat Gulhati; Victoria A Elliott; William C Mustain; Kathleen O'Connor; Andrew J Morris; Manjula Sunkara; Heidi L Weiss; Eun Y Lee; B Mark Evers
Journal:  Cancer Res       Date:  2012-01-19       Impact factor: 12.701

6.  Differential growth and responsiveness to cancer therapy of tumor cells in different environments.

Authors:  Mohammad Alsaggar; Qian Yao; Houjian Cai; Dexi Liu
Journal:  Clin Exp Metastasis       Date:  2015-10-17       Impact factor: 5.150

7.  Therapeutic properties of aerobic training after a cancer diagnosis: more than a one-trick pony?

Authors:  Lee W Jones; Mark W Dewhirst
Journal:  J Natl Cancer Inst       Date:  2014-03-13       Impact factor: 13.506

8.  The Prognostic Value of Cancer Stem Cell Markers (Notch1, ALDH1, and CD44) in Primary Colorectal Carcinoma.

Authors:  Salem Y Mohamed; Randa Mohamed Kaf; Mona Mostafa Ahmed; Amira Elwan; Hassan R Ashour; Amr Ibrahim
Journal:  J Gastrointest Cancer       Date:  2019-12

Review 9.  Targeting and utilizing primary tumors as live vaccines: changing strategies.

Authors:  Xuanming Yang; Eric D Mortenson; Yang-Xin Fu
Journal:  Cell Mol Immunol       Date:  2011-11-21       Impact factor: 11.530

Review 10.  In vivo animal models for studying brain metastasis: value and limitations.

Authors:  Inderjit Daphu; Terje Sundstrøm; Sindre Horn; Peter C Huszthy; Simone P Niclou; Per Ø Sakariassen; Heike Immervoll; Hrvoje Miletic; Rolf Bjerkvig; Frits Thorsen
Journal:  Clin Exp Metastasis       Date:  2013-01-16       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.